

**Cyclophosphamide in Biologic Naïve
Rheumatoid Arthritis patients Resistant to
Traditional DMARDs**

Thesis

*Submitted in Partial Fulfillment of the Master Degree in
Internal Medicine*

Presented by

Asmaa Mortada Abd Ellah
M.B.B.CH

Under Supervision of

Prof.Dr. Howaida Elsayed Mansour
*Professor of Internal Medicine and Rheumatology
Ain-Shams University*

Dr. Noran Osama Ahmed El Azizi
*Assistant Professor of Internal Medicine and
Rheumatology
Ain-Shams University*

Dr. Maha Ahmed El Serwy
*Lecturer of Internal Medicine and Rheumatology
Ain-Shams University*

Faculty of Medicine
Ain-Shams University

2017

List of Contents

Title	Page No.
List of Tables	3
List of Figures.....	5
List of Abbreviations	7
Introduction	1
Aim of the Work	3
Review of Literature	
▪ Rheumatoid Arthritis	4
▪ Cyclophosphamide	59
▪ Cyclophosphamide in Rheumatoid Arthritis	67
Patients and Methods.....	71
Results	78
Discussion.....	103
Summary and Conclusion.....	110
Recommendations	113
References	114
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	ACR /EULAR 2010 classification criteria for RA.....	32
Table (2):	Disease activity indices of RA.....	35
Table (3):	DAS28 score interpretation.....	73
Table (4):	Health assessment questionnaire	74
Table (5):	Description of demographic, laboratory and clinical data of the studied patients at baseline study.....	79
Table (6):	Description of demographic, laboratory and clinical data of the studied patients at the study endpoint.....	82
Table (7):	Comparison between RA patients at study baseline and endpoint regarding clinical and laboratory data	83
Table (8):	Improvement in DAS 28 score at the study endpoint.....	86
Table (9):	Correlation between disease duration with all parameters of the studied patients at baseline.....	89
Table (10):	Correlation between disease duration and other parameters of the studied RA patients at study endpoint	91
Table (11):	Correlation between sex of the studied patients and disease activity markers at study baseline:.....	93
Table (12):	Correlation between sex of the studied patients and disease activity markers at study endpoint.....	95

List of Tables (cont...)

Table No.	Title	Page No.
Table (13):	Correlation between RF and disease activity markers at study endpoint	97
Table (14):	Correlation between ACCP and disease activity markers at study endpoint.....	99
Table (15):	Correlation between CRP at the study base line and HAQ, VAS, DAS score at study endpoint.....	100
Table (16):	Correlation between DAS -28 score at the baseline and DAS-28, HAQ, VAS scores at study endpoint.....	102
Table (17):	Correlation between ESR at the study baseline and HAQ, VAS, DAS score at study endpoint.....	102

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Adaptive and Innate Immune Processes within the Joint in Rheumatoid Arthritis.....	12
Figure (2):	Diagram showing the costimulation-dependent interactions among dendritic cells, T cells, and B cells.....	14
Figure (3):	RA hand deformities	20
Figure (4):	Patient's feet deformed by rheumatoid arthritis.....	21
Figure (5):	RT knee effusion in RA	22
Figure (6):	Serial MRI scans	39
Figure (7):	Eular recommendation for management of RA.....	58
Figure (8):	Visual analogue scale	75
Figure (9):	Sex distribution of the studied RA patients.....	80
Figure (10):	Percentage of RF in studied RA patients.....	80
Figure (11):	Percentage of ACCP in studied RA patients.....	81
Figure (12):	Comparison between ESR, CRP and PLT level, at baseline and at study endpoint.....	85
Figure (13):	Comparison between Hb level and DAS-28 score at baseline and at study endpoint.....	85
Figure (14):	Pie Chart showing improvement in disease activity by DAS- 28 score at the end of the study.....	86

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (15):	Comparison between clinical data at study baseline and endpoint.....	87
Figure (16):	Comparison between HAQ score at study baseline and endpoint.....	87
Figure (17):	Comparison between VAS score at study baseline and endpoint.	88
Figure (18):	Pie Chart showing VAS score in patients pre-treatment with CYC at the study entry.	88
Figure (19):	Pie Chart showing VAS score in patients post-treatment with CYC.....	89
Figure (20):	Correlation between disease duration and SJC.	90
Figure (21):	Correlation between disease duration and Hb level at study endpoint.	92
Figure (22):	Correlation between disease duration and Plt level at study endpoint.....	92
Figure (23):	Males have significantly higher platelets levels at the study baseline.	94
Figure (24):	HAQ score in males and females at the study endpoint.	96
Figure (25):	Correlation between Hb level in patients with positive and negative RF.	98
Figure (26):	Correlation between CRP at the study base line and VAS score at study endpoint.	100
Figure (27):	Correlation between ACCP and Plt level at the study endpoint.....	101

List of Abbreviations

Abb.	Full term
<i>ACPA</i>	<i>Anticitrullinated protein antibodies</i>
<i>ACR</i>	<i>American College of Rheumatology</i>
<i>ALDH</i>	<i>Aldehyde dehydrogenase</i>
<i>AML</i>	<i>Acute myeloid leukemia</i>
<i>CD</i>	<i>Cell of differentiation</i>
<i>CDAI</i>	<i>Clinical Disease Activity Index</i>
<i>COX2</i>	<i>Cyclo-oxygenase 2</i>
<i>CRP</i>	<i>C- reactive protein</i>
<i>CTLA</i>	<i>Cytotoxic T-lymphocyte-associated antigen</i>
<i>CVD</i>	<i>Cardiovascular diseases</i>
<i>CYC</i>	<i>Cyclophosphamide</i>
<i>DAS</i>	<i>Disease activity score</i>
<i>DIP</i>	<i>Distal interphalangeal.</i>
<i>DMARDs</i>	<i>Disease modifying antirheumatic drugs</i>
<i>EAM</i>	<i>Extra articular manifestation</i>
<i>EGPA</i>	<i>Eosinophilic granulomatosis with polyangiitis</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>EULAR</i>	<i>European League Against Rheumatism</i>
<i>FDA</i>	<i>Food and drug administration</i>
<i>GCs</i>	<i>Glucocorticoids</i>
<i>GM-CSF</i>	<i>Granulocyte / macrophage colony-stimulating factor.</i>
<i>GPA</i>	<i>Granulomatosis with Polyangiitis</i>
<i>HAQ</i>	<i>Health assessment questionnaire</i>
<i>HB</i>	<i>Hemoglobin</i>
<i>HCQ</i>	<i>Hydrochloroquine</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>HLA</i>	<i>Human Leucocyte antigen</i>
<i>HRCT</i>	<i>High resolution computed tomography</i>
<i>IC</i>	<i>Immune complex</i>
<i>ICAM-1</i>	<i>Intercellular adhesion molecule-1</i>
<i>Ig</i>	<i>Immunoglobulin</i>
<i>IL</i>	<i>Interleukin</i>
<i>ILD</i>	<i>Interstitial lung disease</i>
<i>IM</i>	<i>Intramuscular</i>
<i>JAK</i>	<i>Janus kinase</i>
<i>JIA</i>	<i>Juvenile inflammatory arthritis</i>
<i>MCP</i>	<i>Metacarpophalangeal</i>
<i>MI</i>	<i>Myocardial infarction</i>
<i>MMP</i>	<i>Metalloproteinases</i>
<i>MPA</i>	<i>Microscopic polyangiitis</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>MS</i>	<i>Multiple sclerosis</i>
<i>MTP</i>	<i>metatarsophalangeal</i>
<i>MTX</i>	<i>Methotrexate.</i>
<i>NHS</i>	<i>National health service</i>
<i>NICE</i>	<i>The National Institute for Health and Care Excellence</i>
<i>NSAIDs</i>	<i>Non steroidal anti-inflammatory drugs</i>
<i>OPN</i>	<i>Osteopontin</i>
<i>PADI</i>	<i>Peptidylarginine-deiminase</i>
<i>PAF</i>	<i>Platelet activating factor</i>
<i>PDGF</i>	<i>Platelet derived growth factor</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>PIP</i>	<i>Proximal interphalangeal.</i>
<i>PLT</i>	<i>Platelets</i>
<i>PRF</i>	<i>Perforin 1 (pore forming protein).</i>
<i>PSc</i>	<i>Progressive systemic sclerosis</i>
<i>PTPN22</i>	<i>Protein tyrosine phosphatase non-receptor type 22</i>
<i>RA</i>	<i>Rheumatoid arthritis</i>
<i>RANKL</i>	<i>Receptor activator of nuclear factor κB.</i>
<i>RF</i>	<i>Rheumatoid factor</i>
<i>SC</i>	<i>Subcutaneous</i>
<i>SD</i>	<i>Standard deviation</i>
<i>SDAI</i>	<i>Simplified Disease Activity Index</i>
<i>SE</i>	<i>Shared epitope</i>
<i>SIADH</i>	<i>Syndrome of inappropriate antidiuretic hormone</i>
<i>SJC</i>	<i>Swollen joint count</i>
<i>STAT</i>	<i>Signal Transducer and Activator of Transcription</i>
<i>SyK</i>	<i>Spleen tyrosine kinase</i>
<i>Th</i>	<i>T helper cell</i>
<i>TJC</i>	<i>Tender joint count</i>
<i>TNF</i>	<i>Tumor necrosis factor</i>
<i>TRAF</i>	<i>TNF receptor-associated factor</i>
<i>URT</i>	<i>Upper respiratory</i>
<i>VCAM-1</i>	<i>Vascular cell adhesion molecule-1</i>

ABSTRACT

There was no significant statistical correlation between patients with positive and negative RF and different disease activity markers except for Hb level showing significant increase in patients with positive RF post-treatment with CYC (P-value=0.042), there was also no significant statistical correlation between patients with positive and negative ACCP and different disease activity markers except for Plt level showing significant decrease in patients with positive ACCP post-treatment with CYC (P-value=0.034).

Higher CRP at baseline in RA patients indicates poor response to treatment and higher VAS at study endpoint.

IV pulse CYC and methylprednisolone (MP) are of a significant benefits in induction of remission in resistant aggressive RA patients who failed to respond to traditional DMARDs.

Keywords: Non steroidal anti-inflammatory drugs - Progressive systemic sclerosis - Protein tyrosine phosphatase non-receptor type 22

INTRODUCTION

Rheumatoid arthritis (RA) is characterized by abnormal proliferation of synoviocytes, leukocyte infiltration, and angiogenesis (*Park et al., 2014*). Epidemiological studies show that RA affects 1% of the population worldwide (*Rojas-Villarraga et al., 2009*).

The therapeutic array of RA includes several categories of medicinal products, of varying potential. There are several criteria for the classification of medicinal products used against this disease, one of the most important and modern of which divides such substances according to their effects on the progress of the disease: symptom-modifying antirheumatic drugs (including non-steroidal anti-inflammatory drugs and corticosteroids), disease-modifying antirheumatic drugs (including various substances, such as gold salts, antimalarials, sulfasalazine, D-penicillamine; non-specific immunosuppressive medication, such as methotrexate, cyclophosphamide, azathioprine and leflunomide) and biological therapy is a recent addition (*Negrei et al., 2016*).

Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations (*Joensuu et al., 2015*).

Cyclophosphamide is an immunosuppressive medicine, it has been found to be effective in treating serious complications of rheumatoid arthritis such as vasculitis. By

interrupting the immune process, cyclophosphamide reduces inflammation and slows joint damage caused by rheumatoid arthritis (*Longo et al., 2012*).

However, by reviewing the literature there were limited studies about the use of cyclophosphamide as antirheumatic drug in patients with rheumatoid arthritis.

AIM OF THE WORK

To evaluate the efficacy of CYC and methyl prednisolone pulse therapy in induction of remission in biologic naïve RA patients resistant to conventional DMARDs and can't afford biological treatment.

Chapter 1

RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovial tissue that leads to damage of cartilage and bone, resulting in irreversible joint destruction (*Smigielska-Czepiel et al., 2014*). More aggressive forms of RA also involve extra-articular tissues, causing lung inflammation, splenomegaly with cytopenia, skin nodules and vasculitis (*Fleischman et al., 2012*).

Epidemiology:

The prevalence of RA is relatively constant in many populations, at 0.5-1% (*Uhlig, 2014*). The prevalence of RA in rural Egypt is 0.29% similar to other oriental rural populations but lower than western populations (*Abdel Tawab et al., 2009*).

Women are 3 times more often than men. Onset is most frequent between the ages of 40 and 50, but people of any age can be affected (*Vollenhoven 2009*).

Mortality rates are more than twice as high in patients with RA as in the general population (*Choy, 2012*).

Etiology of RA:

The exact cause of RA is unknown. It is the result of an environmental exposure or “trigger” in a genetically susceptible individual (*Gibofsky, 2012*).

1. Hormonal factors:

The predominance of RA in females suggests a role for hormonal factors, estrogens stimulate the immune system, and low testosterone levels have been reported in men with RA (*Tobon et al., 2010*). Female sex hormones may play a protective role in RA. For example, the use of the oral contraceptives pills and pregnancy are both associated with a decreased risk (*Alan and Jacqueline, 2012*). One possible explanation to this finding is that hormone replacement therapy (HRT) protects against the production of anti-citrullinated protein-antibodies (ACPA) (*Tobon et al., 2010*).

Improvement occurs for 50 to 70% of patients by the end of the first trimester and is usually sustained throughout pregnancy. However, within 3 months of delivery, relapse is observed in 90% of patients (*Shammas et al., 2010*). Both female subfertility and the immediate postpartum period after a first pregnancy (especially when breastfeeding) appear to increase the risk of RA (*McInnes and Schett, 2011*).